Growing vascular endothelial cells express somatostatin subtype 2 receptors

JC Watson1, DA Balster2, BM Gebhardt1,5, TM O’Dorisio6, MS O’Dorisio7, GD Espenan2, GJ Drouant1 and EA Woltering1,4,5,8

Departments of Surgery1, Ophthalmology2 and Radiology3, The Stanley S. Scott Cancer Center4, The Neuroscience Center of Excellence5, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112; The Ohio State University Departments of Medicine6 and Pediatrics7, Columbus, Ohio 43210, and The Veterans Administration Medical Center8, New Orleans, Louisiana 70112, USA

Summary We hypothesized that non-proliferating (quiescent) human vascular endothelial cells would not express somatostatin receptor subtype 2 (sst 2) and that this receptor would be expressed when the endothelial cells begin to grow. To test this hypothesis, placental veins were harvested from 6 human placentas and 2 mm vein disks were cultured in 0.3% fibrin gels. Morphometric analysis confirmed that 50–75% of cultured vein disks developed radial capillary growth within 15 days. Sst 2 gene expression was determined by reverse transcription-polymerase chain reaction (RT-PCR) analysis of the RNA from veins before culture and from tissue-matched vein disks that exhibited an angiogenic response. The sst 2 gene was expressed in the proliferating angiogenic sprouts of human vascular endothelium. The presence of sst 2 receptors on proliferating angiogenic vessels was confirmed by immunohistochemical staining and in vivo scintigraphy. These results suggest that sst 2 may be a unique target for antiangiogenic therapy with sst 2 preferring somatostatin analogues conjugated to radioisotopes or cytotoxic agents. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: somatostatin; somatostatin receptors; receptor subtypes; angiogenesis; vascular endothelium; gene expression

Angiogenesis is a tightly regulated process that normally occurs during embryonic development and is suppressed in adult life. We have previously demonstrated that somatostatin (SRIF) analogues will inhibit angiogenesis in the chicken chorioallantoic membrane (CAM) and in the rabbit corneal micropocket models (Woltering et al, 1991; Patel et al, 1994; Barrie et al, 1993; Conway et al, 1996). These observations have been confirmed by Danesi et al, who demonstrated that somatostatin analogues will inhibit angiogenesis in the CAM model and will inhibit the proliferation of human umbilical ven endothelial cells (HUVECs) in culture (Danesi et al, 1997). In our previous studies, we demonstrated that SRIF-induced inhibition of angiogenesis in the CAM is G-protein- adenylate cyclase-, and calcium-dependent (Patel et al, 1994). We have also shown that the ability of a somatostatin analogue to inhibit angiogenesis is proportional to its sst 2-binding affinity and its ability to inhibit growth hormone release, a sst 2-dependent process (Woltering et al, 1997). These observations imply that endothelial cells growing from human blood vessels express sst 2. External scintigraphic scanning with the sst 2-prefering analogue, 111In-pentetreotide, has demonstrated binding to cells in malignant tissue and to cells in non-malignant tissue in which angiogenesis is occurring but not to normal blood vessels. Similarly, van Hagen et al demonstrated that 111In-pentetreotide localizes to active rheumatoid joints but not to osteoarthritic joints (van Hagen et al, 1994). Reubi et al, using autoradiographic techniques have demonstrated that proliferating human tumoral vessels bind 111I-tyr3-octreotide, a sst 2-preferring radioligand, while distant quiescent vessels do not (Reubi et al, 1994, 1996; Danzler and Reubi, 1999). Based on these observations, we hypothesized that non-proliferating human vascular endothelial cells do not express sst 2 but these receptors are expressed when endothelial cells proliferate. To test this hypothesis, normal placental veins were harvested from 6 human placentas obtained immediately following delivery. RNA was harvested from quiescent (native) placental vessels and from vessel fragments which had been cultured in vitro. In this culture system, we have investigated changes in gene expression as vascular endothelial cells begin to sprout, migrate, and proliferate (Watson et al, 1996). Previous work in our laboratories using this culture system revealed that the gene for a vascular endothelial growth factor (VEGF) receptor, kdr, is expressed in angiogenic vein disks but not in placental vessels in which endothelial growth is not occurring.

METHODS

In vitro culture of human placental veins

Fresh human placentas were obtained from 6 anonymous donors following guidelines established by the LSU Institutional Review Board, Protocol #2828. Placental veins were trimmed of surrounding tissue, opened longitudinally and 2 mm diameter disks prepared using a sterile skin biopsy punch. Residual placental vein tissue was placed in Ultraspec® RNA isolation solution (Biotex, Inc, Houston, TX) for subsequent RNA extraction. Vein disks (N = 100/asssay) were incorporated into 0.3% fibrin gels in complete tissue culture medium containing 20% fetal
bovine serum (FBS), &-amino caproic acid, antibiotics and antimicrobials. Fibrin gels were overlaid with tissue culture medium consisting of minimal essential medium (MEM, Gibco, Grand Island, NY), supplemented with 10% FBS, penicillin, streptomycin and fungizone according to methods outlined by Watson et al and Brown et al (Brown et al, 1996; Watson et al, 1996). Cultured dishes were incubated in a 5% CO2/95% air atmosphere at 37°C for 15 days and observed daily with an inverted microscope. At 15 days, cultures exhibiting endothelial cell growth and those not exhibiting an angiogenic response were collected for RNA isolation. Separate experiments with cultured, nonangiogenic vein disks were performed to determine if their failure to proliferate was due to poor cell viability. The MTT cell viability assay (Promega Corporation, Madison, WI) confirmed that these disks contained viable cells even though they did not exhibit an angiogenic response.

**Reverse transcription-polymerase chain reaction (RT-PCR) analysis of gene expression**

Venous tissue collected at the time of preparation of the disks, cultured disks that did not develop endothelial sprouts and disks which developed sprouts were collected in separate RNase-free tubes and homogenized in an RNA isolation solution (RNAzol, Biotex, Houston, TX). RNA from each sample was quantitated by absorbance at 260/280 spectrophotometric analysis. 500 ng of RNA was reverse transcribed in the presence of random hexamer primers using a reverse transcription system (Perkin-Elmer Applied Biosystems, Carson City, CA). The expression of the sst 2 gene and the constitutively expressed gene for glyceraldehyde-6-phosphodehydrogenase (GAPDH) was determined by amplifying the cDNAs from non-proliferating and from proliferating placental endothelial cells. Following 35 amplification cycles, the gene products were analysed on 2% agarose gels stained with ethidium bromide. Visualization of the amplified gene products was performed with an Eagle-Eyell® gel documentation system (Stratagene, Inc, La Jolla, CA) (Figure 1). Nucleotide sequences of the primers and probes used are given in Table 1.

**Table 1 Primers and probes used in this study**

| Primers          | Probes         |
|------------------|----------------|
| sst 2 antisense  | GAG GTG AAA TGG AAT GGA TAG CCA TGT GTG |
| sst 2 sense      | GGT ATG GGT GTC AAC CAG GAC |
| GAPDH antisense  | GCA TCT ACT GGC GTC TTC AGC |
| GAPDH sense      | GAA TTC AGA TAT CGG TTT GGA G |
|                  | AGC CAT GGA CAT GGC GGA TGA G |

*Primers and probes were synthesized by the Core Laboratories of the LSU Health Sciences Center.

**Southern hybridization**

Southern hybridization was used to confirm the identity of the amplified gene products. DNA probes, complementary to an internal sequence of the amplified sst 2 and GAPDH amplicons (Table 1), were labelled with biotin (Ready-To-Go beads, Pharmacia Biotech, Piscataway, NJ). 10 mg of labelled probe in Express Hyb® hybridization solution was incubated with nitrocellulose membranes (Tropilon Plus, Tropix, Bedford, MA) to which were bound the amplified products. The hybridized biotin-labelled probes were detected using the Southern-Light® detection system (Tropix). Autoradiography was performed on X-ray film (X-OMAT AR, Kodak Corp., Rochester, NY).

**Localization of radiolabelled somatostatin analogues in angiogenic vessels in vivo**

Nude mice (Harlan Sprague Dawley, Indianapolis, IN) were injected in the hindquarter with 1 × 10⁶ SKNSH human neuroblastoma tumour cells, in accordance with LSUHSC Institutional Animal Care and Use Committee approved Protocol #1806. SKNSH cells do not express sst 2 as measured by both RT-PCR and in vitro binding assays (O’Dorisio et al, 1994). Injection sites were observed for 2–3 months until tumours grew to 2 cm in diameter. Mice were injected in the tail vein with 3 mCi of 125I-WOC4a[DTyr-Tyr-DTyr-Cys-Phe-DTrp-Lys-Thr-Cys-Thr], an sst 2-prefering somatostatin analogue (Woltering et al, 1998). We have previously shown that this radioiodinated analogue has a high binding affinity for sst 2 (Kd~1nM) and will induce receptor-specific cytotoxicity in human (IMR32) neuroblastoma cells (Meyers et al, 1998). Background counts were allowed to clear for 5 days, and the mice were then scanned and radiographed. Because of the low energy emissions of 125I, mice were scanned on both their ventral and dorsal surfaces.

**Preparation of sst 2 antiserum**

An oligonucleotide corresponding to the N terminal 45 amino acids of sst 2 was cloned into pET-32a(+) vector (Novagen, Madison, WI) as a C terminal fusion to thioredoxin using T4DNA ligase (TA cloning kit, Invitrogen, Carlsbad, CA). The resulting plasmid was sequenced in order to confirm that the insert was in the correct orientation and that the sequence matched the native gene sequence. The plasmid was transformed into the AD494 bacterial host strain (Novagen, Madison, WI) and plated on LB plates containing ampicillin and kanamycin overnight at 37°C.
Colonies were picked and cultured in 20 ml LB medium (containing 100 µg ml⁻¹ ampicillin and 30 µg ml⁻¹ kanamycin) overnight at 37°C in a shaking incubator. Bacterial cultures were diluted 1:50 with fresh medium and cultured 3 to 4 hours until the O.D. at 600 nm was greater than 0.6. Isopropylthio-β-D-galactosidase (IPTG) was added to a final concentration of 1 mM to induce protein expression. After 2 hours bacteria were collected by centrifugation at 8000 g for 10 minutes. The pellets were resuspended in start buffer (1 x PBS and 10 Mm imidazole, pH 7.4) and sonicated using a Polytron® at setting 7 with 5 second bursts for 1 minute to release the sst 2 peptide. Supernatants were collected and pellets sonicated again. The sst 2-containing supernatant was filtered through a 0.45 m filter (Nalgene, Rochester, NY) and the protein concentration was determined. The peptide was purified using the Pharmacia His Trap® column system (Amersham Pharmacia Biotech, Piscataway, NJ), dialysed against a 0.9% NaCl solution overnight at 4°C, and concentrated using a Centriplus® concentrator (Amicon, Beverly, MA).

3 kg male rabbits were immunized with 500 µg sst 2 peptide in 0.5 ml 0.9% NaCl emulsified with an equal volume of Freund’s complete adjuvant. The emulsion was injected both intramuscularly and intradermally. Four booster injections (100 µg peptide) were given at 3-week intervals. Serum was collected before each booster injection and 3 weeks after the final injection and stored at –20°C. This antibody has been previously characterized by Balster et al (2001) and Albers et al (2000).

**Immunohistochemical staining**

Placental vein disks were cultured in 48-well plate membrane-bottomed inserts. Disks which visually exhibited an angiogenic response were fixed in 10% neutral-buffered formalin and embedded in paraffin using standard tissue processing techniques. Serial 4 µm slices were obtained and every tenth slide stained with haematoxylin and eosin until the portion of the block containing the vessel disk was reached. Factor VIII staining was performed to confirm that vascular endothelial cells were present in the outgrowths.

Paraffin sections of the vessel/fibrin clot were deparaffinized and incubated in 3% H₂O₂ for 15 minutes at room temperature, washed in distilled water (dH₂O) and placed and preheated in Antigen Retrieval® (Biogenix, San Ramon, CA) solution. Slides were microwaved for 10 minutes on medium power and left in sealed container for 15 minutes, followed by washing in dH₂O 3 times and then in OptiMax Wash Buffer® (Biogenix). Slides were incubated in PeroxDaze 1® (Biocare Medical, Walnut Creek, CA) for 15 minutes at room temperature, again washed in OptiMax buffer, and incubated in Power Block® (Biogenix, San Ramon, CA) for 10 minutes. A 1:1000 dilution of sst 2 antiserum (or a 1:1000 dilution of preimmune serum) in diluent buffer (Biomedia, Foster City, OH) was added to separate slides and incubated at 4°C overnight. Slides were washed in OptiMax Wash Buffer® for 20 minutes at room temperature. Secondary antibody (Biogenix multilink super sensitive biotinylated antibody) was added to the sections which were incubated for 20 minutes at room temperature. Slides were rinsed in OptiMax Wash Buffer® in a minimum of 20 minutes, followed by incubation in conjugated streptavidin (Biogenix) for 20 minutes. Slides were rinsed in OptiMax Wash Buffer® for 20 minutes. AEC (3-amin o-9-ethyl-carbazole) chromogen was applied for 10 to 20 minutes, followed by rinsing in OptiMax Wash Buffer® and dH₂O. Slides were lightly counterstained with haematoxylin for 10 seconds followed by 3 seconds in ammonia water, rinsed in dH₂O, coverslipped with Crystal mount, placed in a 60°C oven for 15 minutes and the cover slip sealed with Permount (Biogenix, San Ramon, CA).

**RESULTS**

**Gene expression in quiescent, proliferating and non-proliferating placental vein cultures**

We analysed sst 2 receptor mRNA expression in non-proliferating vein and proliferating placental vein endothelial cells obtained from 6 placentas. In each of the placental samples, we found that sst 2 gene expression was absent in non-proliferating endothelial cells but was present in the proliferating endothelium (Figure 1A). GAPDH mRNA was expressed in all samples (Figure 1B). Sst 2 gene expression was confirmed by Southern hybridization analysis of the amplified gene products derived from proliferating placental vein endothelial cells. Hybridization of the amplified gene product with a sst 2 probe revealed a single product of the expected molecular weight (Figure 2).

**Localization of radiolabelled somatostatin analogues in angiogenic vessels in vivo**

Scans and radiographs were performed in register so that we could compare relative radioligand uptake in the liver (normal route of excretion) (Figure 3A) and in the tumour (Figure 3B). These scans revealed significant radioligand uptake in the SKNSH tumour even though the tumour cells do not express somatostatin receptors. Alternatively, normal (non-proliferating) blood vessels in non-tumour-bearing sites did not accumulate the radioligand, implying that binding of the radioligand in the tumour was due to sst 2 receptor expression on the angiogenic blood vessels supplying the tumour.

**Immunohistochemical staining of vein disks**

To confirm the endothelial nature of the sprouts from the vein disks, factor VIII, staining was performed (Figure 4). Immunohistochemical staining for sst 2 receptors revealed the presence of the receptor protein on cells forming the vascular sprouts (Figure 5). The vein disk did not stain for sst 2 receptors except at the periphery of the disk, the origin of the neovascular sprouts. This staining pattern was not seen in the non-angiogenic disks incubated in the anti-sst 2 antisera (not shown). Neither the angiogenic nor the non-angiogenic vein disks exhibited staining following incubation in the nonimmune serum (Figure 6). Previous work with this
Antibody demonstrated sst 2 staining on the endothelial cells of peritumoral vessels in a mouse tumour xenograft model. Absorption of the sst 2 antibody with sst 2 antigen ablated the immunohistochemical staining of the peritumoral vessels (Albers et al, 2000).

**DISCUSSION**

We have previously demonstrated in both the chicken chorioallantoic membrane (CAM) assays and the rabbit bFGF-induced corneal micropocket angiogenesis models that octreotide acetate will inhibit angiogenesis (Woltering et al, 1991; Barrie et al, 1993; Patel et al, 1994; Conway et al, 1996). This inhibition is proportional to a somatostatin analogue’s ability to inhibit growth hormone which in turn is proportional to the analogue’s binding affinity for sst 2 (Woltering et al, 1997). Inhibition of angiogenesis in the CAM model is G-protein-, adenylate cyclase-, and calcium-dependent similar to somatostatin inhibition of peptide release from neuroendocrine cells (Patel et al, 1994). Based on these observations, it appears that similar receptors and post-receptor signal transduction pathways are responsible for somatostatin’s ability to inhibit peptide release, tumour growth, and angiogenesis (Bhatena et al, 1981; Thompson et al, 1986; Woltering et al, 1986; Wynick and Bloom, 1991).

The widespread use of radiolabelled somatostatin analogues in patients with neuroendocrine tumours has demonstrated that these

**Figure 3** (A) Scintographs and radiographs were performed in register to compare relative radioligand uptake in the liver (normal route of excretion). The SKNSH tumour (sst 2-negative) shows intense uptake of a radiolabelled sst 2-preferring somatostatin analogue. (B) Scintographs and radiographs were performed in register to compare relative radioligand uptake in the tumour. The SKNSH tumour (sst 2-negative) shows intense uptake of a radiolabelled sst 2-preferring somatostatin analogue
that prostate cancers will selectively bind radiolabelled somatostatin analogues, however, the level of binding is less than that seen in endocrine neoplasms (Nilsson et al, 1995; Kalkner et al, 1998). Other tumours have been imaged with radiolabelled analogues and in many instances subsequent evaluation of these tumours by autoradiography shows little or no uptake or binding of the radiolabelled analogue by tumour cells. We believe that radiolabelled analogue binding to tumour-associated angiogenic blood vessels may explain tumour imaging in sst 2-negative tumours. In almost all tumour types, high-grade lesions have more intense ligand binding than low-grade lesions, an observation consistent with a poorly differentiated tumour developing a more intense angiogenic response.

These findings may have considerable clinical relevance. An angiogenic response is required for a tumour to grow beyond a diameter of 2 mm. The expression of sst 2 in angiogenic vessels implies that tumours greater than 2 mm in diameter might bind sst 2-preferring radiolabelled somatostatin analogues either to their
tumour cells, their angiogenic neovessels, or both. This observation provides encouragement for the development of specific sst 2 targeted therapy in tumours with homogeneous or heterogeneous receptor distribution.

Other investigators have noted that tumour cell expression of sst 2 is heterogeneous and that radiolabelled somatostatin analogue therapy is best accomplished by the use of high-energy radioisotopes (Bootsma et al., 1993). While the heterogeneous expression of sst 2 on tumour cells is ubiquitous, it appears that all proliferative neovessels homogeneously express this receptor. This difference in receptor expression may permit the use of low energy radioisotopes for therapy (McCarty et al., 1998; Espenan et al., 1999). Sst 2-targeted applications may include intraoperative gamma localization of occult primary tumours, and intraoperative gamma detection of microscopically positive primary tumour resection margins (Schirmer et al., 1993; Woltering et al., 1994; Martinez et al., 1995; Cuntz et al., 1999). This sensitive technique may also allow the detection of small deposits of tumour in lymph nodes or in areas outside the normal field of resection (Woltering et al., 1994). Other applications of sst 2-targeted techniques include external scintigraphic imaging and in situ radiotherapy. Recent reports on the use of low energy Auger electron emitters, such as 11In-pentetreotide for therapy of sst 2-expressing tumours are encouraging (McCarty et al., 1998; Espenan et al., 1999). Others have used high-energy radiolabelled somatostatin analogues for therapy, hoping that higher energy radioisotopes will induce cell death in adjacent receptor-negative cells (Zamora et al., 1997; Espenan et al., 1999). Somatostatin analogues can also be conjugated to chemotherapeutic agents or toxins and may provide highly targeted tumoricidal or angiocidal therapy (Plowntownski et al., 2000).

The results of this study reveal that sst 2 expression occurs when vascular endothelial cells begin to grow. The finding paves the way for the development of a highly specific target for anti-angiogenic therapy using sst 2-prefering somatostatin analogues.

ACKNOWLEDGEMENTS

Supported in part by NIH/NEI grant #P30 EY02377 to the Department of Ophthalmology, Louisiana State University Health Sciences Center

REFERENCES

Albers AR, O’Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, Hoeger C, Rivier J, Wenger GD, O’Dorisio TM and Qualman SJ (2000) Somatostatin receptor gene expression in neoblastoma. Reg Peptider 88: 61–73
Balster DA, O’Dorisio MS, Summers MA and Turman MA (2001) Segmental expression of somatostatin receptor subtypes sst 1 and sst 2 in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 280(3): F457–F465
Barrie R, Woltering EA, Hajarizadeh H, Murphy WA, Drouant GJ, Fusselier J, Espenan GD, Maloney TJ and Woltering EA (1998) Multiply radiolabeled somatostatin analogues induce receptor-specific cytotoxicity. J Surg Res 76: 154–157
Nilsson S, Reubi JC, Kalkner KM, Laisice JA, Horisberger U, Olerud C and Westlin JE (1995) Metastatic hormone-refractory prostate adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res 55(23 Suppl): 5805s–5810s
O’Dorisio MS, Chen F, Wray DA, Qualman SJ and O’Dorisio TM (1994) Identification of somatostatin receptors on human neuroblastomas. Cell Growth and Differentiation 5: 1–8
Patel PC, Barrie R, Hill N, Landeck S, Kurzawova D and Woltering EA (1994) Post-receptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 116: 1148–1154
Plowntownski A, Schally AV, Nagy A, Kizars H, Hebert F and Holmsen G (2000) Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 60(11): 2996–3001
Reubi JC, Horisberger U and Laisise JA (1994) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interactions? Int J Cancer 56: 681–689
Reubi JC, Schaar JC, Laisise JA and Waser B (1996) Somatostatin receptors and their subtypes in human tumors and peritumoral vessels. Metabolism: Clinical and Experimental 8(Suppl 1): 39–49
Schirmer WJ, O’Dorisio TM, Schirmer TP, Mjozsik CM, Hinkle GH and Martin EW (1993) Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surg 114: 745–749
Thompson CS, O’Dorisio TM and Woltering EA (1986) Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma. Digestion 27(Suppl 1): 62–65
van Hagen PM, Markusse HM, Lambertis SW, Kwekkenboom DJ, Reubi JC and Krenning EP (1994) Somatostatin receptor imaging: the presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 37: 1521–1528
Watson JC, Geballard BM, Alperin-Lea RC, Redmann JC and Woltering EA (1996) Initiation of apr transgene transcription is associated with the conversion of human vascular endothelium to an angiogenic phenotype. Surfogum 47: 462–466
Woltering EA, Ellison EC, O’Dorisio TM, Sparks J, Howe B and Dyben T (1986) Somatostatin-like peptides after calcium but not secretin sensitivity of gastrinoma cells. J Surg Res 40: 605–608
Woltering EA, Barrie R, O’Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Roberston J and Fassler J (1991) Somatostatin analogs inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50: 245–251
Woltering EA, Barrie R, O’Dorisio TM, O’Dorisio MS, Nance R and Cook DM (1994) Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surg 116(6): 1139–1141
Woltering EA, O’Dorisio MS and O’Dorisio TM (1995) The role of somatostatin analogs in the management of cancer patients. In Principles and Practice of Oncology Updates De Vita VT Jr. (ed.) pp. 31–47. Lippincott Healthcare Publications: Philadelphia

© 2001 Cancer Research Campaign
Woltering EA, Alperin-Lea RC, Sharma C, Keenan EJ, Kurozawa D and Barrie R (1997) Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15: 77–88

Woltering EA, O’Dorisio MS, Murphy WA, Chen F, Drouant GJ, Esperan GD, Fisher DR, Sharma C, Diaco DS, Maloney TJ, Fuselier J, Nelson JA, O’Dorisio TM and Coy DH (1999) Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs. J Peptide Res 53: 201–206

Wynick D and Bloom SR (1991) The use of long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Endocrinol Metabol 73: 1–4

Zamora PO, Marek MJ and Knapp FF Jr (1997) Preparation of 188Re-RC-160 somatostatin analog: a peptide for local/regional radiotherapy. Appl Rad & Isotopes 48(3): 305–309